BiotechTube

Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) + Placebo + Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Frailty

Conditions

Frailty

Trial Timeline

Mar 3, 2014 → Oct 2, 2020

NCT ID
NCT02065245

About Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) + Placebo + Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)

Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) + Placebo + Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) is a phase 1/2 stage product being developed by Longeveron for Frailty. The current trial status is completed. This product is registered under clinical trial identifier NCT02065245. Target conditions include Frailty.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02065245Phase 1/2Completed

Competing Products

3 competing products in Frailty

See all competitors
ProductCompanyStageHype Score
Transdermal testosterone gel (Testogel 1% ) + Matched transdermal placebo gelBayerApproved
82
Longeveron Mesenchymal Stem Cells (LMSCs)LongeveronPhase 2
44
Longeveron Mesenchymal Stem Cells (LMSCs) + Fluzone High Dose VaccineLongeveronPhase 1/2
33

Other Products from Longeveron

Allogeneic MSCPhase 2
44
Longeveron Mesenchymal Stem Cells (LMSCs)Phase 2
44
Lomecel-B medicinal signaling cellsPhase 2
44
Peripheral Intravenous (IV) infusion of LMSCsPhase 2
44
Longeveron Mesenchymal Stem CellsPhase 1/2
33